| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
60,930,000 |
| Market
Cap: |
1.55(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$10.11 - $25.45 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
10,000 |
1,687,666 |
| Total Buy Value |
$0 |
$0 |
$138,828 |
$30,291,232 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
3 |
| Total Shares Sold |
0 |
75,715 |
115,161 |
179,650 |
| Total Sell Value |
$0 |
$1,108,986 |
$1,602,723 |
$2,646,007 |
| Total People Sold |
0 |
5 |
6 |
6 |
| Total Sell Transactions |
0 |
14 |
25 |
43 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2019-01-11 |
4 |
AS |
$26.00 |
$7,800 |
D/D |
(300) |
0 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2019-01-11 |
4 |
OE |
$1.89 |
$567 |
D/D |
300 |
300 |
|
- |
|
| Kelly Thomas Patrick |
Chief Financial Officer |
• – – |
2019-01-07 |
4 |
AS |
$25.18 |
$125,900 |
D/D |
(5,000) |
0 |
|
- |
|
| Kelly Thomas Patrick |
Chief Financial Officer |
• – – |
2019-01-07 |
4 |
OE |
$1.89 |
$9,450 |
D/D |
5,000 |
5,000 |
|
- |
|
| Martin Daniel C. |
Chief Commercial Officer |
• – – |
2018-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2018-03-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
91,779 |
55,270 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2018-03-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
91,779 |
91,779 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2017-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
147,049 |
147,049 |
|
- |
|
| New Leaf Bpo Associates I, L.p. |
10% Owner |
– – • |
2017-10-02 |
4 |
B |
$17.00 |
$6,375,000 |
I/I |
375,000 |
2,146,308 |
1.5 |
- |
|
| New Leaf Bpo Associates I, L.p. |
10% Owner |
– – • |
2017-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,729,140 |
1,771,308 |
|
- |
|
| Ratcliffe Liam |
Director |
– • • |
2017-10-02 |
4 |
B |
$17.00 |
$6,375,000 |
I/I |
375,000 |
2,146,308 |
2.25 |
- |
|
| Ratcliffe Liam |
Director |
– • • |
2017-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,729,140 |
1,771,308 |
|
- |
|
| Brightstar Associates Llc |
10% Owner |
– – • |
2017-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,572,370 |
16,572,370 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2017-08-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
55,270 |
147,049 |
|
- |
|
| Flynn Daniel Lee |
Chief Scientific Officer |
• – – |
2017-08-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
55,270 |
0 |
|
- |
|
290 Records found
|
|
Page 12 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.04%) 
